

C1
C2
domain starts with the aminoacid in position 179. A signal peptide of 17 aminoacid is present in the N-terminal portion of the protein.--

IN THE CLAIMS

Amend the claims as follows.

C2
1. (Amended) Orally, parenterally, transdermally or subcutaneously administrable pharmaceutical composition containing, as active ingredient, the amino acid sequence of the long pentraxin PTX3, and a pharmacologically acceptable excipient.

C3
3. (Amended) Composition according to claim 2, in which the sequence of the long pentraxin PTX3 is the sequence of human PTX3.

C4
5. (Amended) Composition according to claim 4, for the treatment of diseases caused by bacteria, fungi, protozoa or viruses.

REMARKS

Reconsideration is requested.

Claims 1-8 and 12-16 are pending. The Examiner's comment regarding rejoinder of claims 13-16 at an appropriate time is acknowledged, with appreciation.

The PTO-1449 Form returned with the Office Action dated December 20, 2001 (Paper No. 14) did not include the Examiner's initials in the left hand margin on the line listing WO 93 21313, as described in MPEP §609. A further copy of the previously filed PTO-1449 Form is attached and return of a completely initialed copy of the same is requested. The undersigned notes the Examiner has signed and dated the entirety of